These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28111331)

  • 1. Assessing molecular scaffolds for CNS drug discovery.
    Mayol-Llinàs J; Nelson A; Farnaby W; Ayscough A
    Drug Discov Today; 2017 Jul; 22(7):965-969. PubMed ID: 28111331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.
    Wager TT; Hou X; Verhoest PR; Villalobos A
    ACS Chem Neurosci; 2010 Jun; 1(6):435-49. PubMed ID: 22778837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technically Extended MultiParameter Optimization (TEMPO): An Advanced Robust Scoring Scheme To Calculate Central Nervous System Druggability and Monitor Lead Optimization.
    Ghose AK; Ott GR; Hudkins RL
    ACS Chem Neurosci; 2017 Jan; 8(1):147-154. PubMed ID: 27741392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery.
    Wager TT; Hou X; Verhoest PR; Villalobos A
    ACS Chem Neurosci; 2016 Jun; 7(6):767-75. PubMed ID: 26991242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modular synthesis of thirty lead-like scaffolds suitable for CNS drug discovery.
    Mayol-Llinàs J; Farnaby W; Nelson A
    Chem Commun (Camb); 2017 Nov; 53(91):12345-12348. PubMed ID: 29099137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
    Nienaber V
    Curr Top Med Chem; 2009; 9(18):1688-704. PubMed ID: 19929834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unified lead-oriented synthesis of over fifty molecular scaffolds.
    Doveston RG; Tosatti P; Dow M; Foley DJ; Li HY; Campbell AJ; House D; Churcher I; Marsden SP; Nelson A
    Org Biomol Chem; 2015 Jan; 13(3):859-65. PubMed ID: 25408068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.
    Safavi M; Sabourian R; Abdollahi M
    Expert Opin Drug Discov; 2016 Oct; 11(10):939-56. PubMed ID: 27454411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain.
    Rankovic Z
    J Med Chem; 2017 Jul; 60(14):5943-5954. PubMed ID: 28388050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.
    Summerfield SG; Zhang Y; Liu H
    J Pharmacol Exp Ther; 2016 Aug; 358(2):294-305. PubMed ID: 27194478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and regulatory requirements and challenge for CNS drug development.
    Gad SC
    Neurobiol Dis; 2014 Jan; 61():39-46. PubMed ID: 24090873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: a mini review.
    Kuo A; Smith MT
    J Neurosci Methods; 2014 Aug; 233():166-71. PubMed ID: 24937765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tool to utilize adverse effect profiles to identify brain-active medications for repurposing.
    McCoy TH; Perlis RH
    Int J Neuropsychopharmacol; 2015 Feb; 18(3):. PubMed ID: 25673184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applicability of a blood-brain barrier specific artificial membrane permeability assay at the early stage of natural product-based CNS drug discovery.
    Könczöl A; Müller J; Földes E; Béni Z; Végh K; Kéry A; Balogh GT
    J Nat Prod; 2013 Apr; 76(4):655-63. PubMed ID: 23565574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demystifying brain penetration in central nervous system drug discovery. Miniperspective.
    Di L; Rong H; Feng B
    J Med Chem; 2013 Jan; 56(1):2-12. PubMed ID: 23075026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality by design in lead optimization: a new strategy to address productivity in drug discovery.
    Rossi T; Braggio S
    Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptorome screening for CNS drug discovery.
    Vortherms TA; Roth BL
    IDrugs; 2005 Jun; 8(6):491-6. PubMed ID: 15906196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.
    Alavijeh MS; Chishty M; Qaiser MZ; Palmer AM
    NeuroRx; 2005 Oct; 2(4):554-71. PubMed ID: 16489365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal chemical properties of successful central nervous system drugs.
    Pajouhesh H; Lenz GR
    NeuroRx; 2005 Oct; 2(4):541-53. PubMed ID: 16489364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.